Bronchodilating and Bronchoprotective Effects of Deep Inspirations - Full Text View

Purpose

The objectives of this research are to compare (i) the bronchodilating and (ii) the bronchoprotective effects of deep inspirations (DIs) in individuals with: (a) asthma, (b) CVA, (c) methacholine-induced cough but normal airway sensitivity and .

(d) in healthy individuals (without asthma, chronic cough or asymptomatic airway hyperresponsiveness).

Hypotheses:

i. The bronchodilating effect of a DI will be: (a) absent or impaired in individuals with classic asthma; (b) impaired in individuals with CVA; (c) preserved in individuals with methacholine-induced cough but normal airway sensitivity; and (d) preserved in healthy individuals (without asthma, chronic cough or asymptomatic airway hyperresponsiveness).

ii. The bronchoprotective effect of a DI will be: (a) absent in individuals with classic asthma; (b) impaired in individuals with CVA; (c) preserved in those with methacholine-induced cough but normal airway sensitivity; and (d) preserved in healthy individuals (without asthma, chronic cough or asymptomatic airway hyperresponsiveness).

iii. Healthy individuals without asthma, chronic cough, or asymptomatic airway hyperresponsiveness, will not cough, or develop significant dyspnea, small airways obstruction or dynamic hyperinflation during high-dose methacholine bronchoprovocation.

Condition	Intervention
Asthma Cough	Other: Methacholine(MCh) Challenge Testing


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: No masking Primary Purpose: Basic Science
Official Title:	Bronchodilating and Bronchoprotective Effects of Deep Inspirations in Asthma, Cough Variant Asthma and Chronic Cough With Normal Airway Sensitivity and Sensory-Mechanical Responses to High-Dose Methacholine in Healthy Normal Subjects

Resource links provided by NLM:

MedlinePlus related topics: Cough

U.S. FDA Resources

Further study details as provided by Dr. Diane Lougheed, Queen's University:

Primary Outcome Measures:

Mid expiratory flows [ Time Frame: Time frame of the methacholine challenge varies between individuals. At provocative concentration of methacholine causing a 20% and 50% decline in FEV1 (PC20 and PC50 respectively). On average, these occur about 15-25 minutes into the challenge test. ]
The bronchodilating effect of a DI will be examined using responses to high-dose methacholine challenge testing (Visit 1) in these subgroups by comparing the mid-expiratory flow difference between the partial (PEF) and full maximal flow-volume (MEF) loops at 40% above Residual Volume (RV) from the forced vital capacity (FVC) (PEF40 and MEF40 respectively) at PC20 and PC50 with that recorded at baseline.

Secondary Outcome Measures:

percent fall in FEV1 [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
The bronchoprotective effect of a deep inspiration will be measured by the difference between the percent fall in FEV1 following administration of methacholine using modified single-dose methacholine challenge tests on Visits 2 and 3 (with or without preceding deep inspirations)
respiratory system reactance (X5) [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
The bronchoprotective effect of a DI will be also examined by comparing mechanical responses to methacholine using impulse oscillometry (IOS). Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.
peripheral resistance (R5-R20) [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
The bronchoprotective effect of a DI will be also examined by comparing mechanical responses to methacholine using impulse oscillometry (IOS). Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.
Central airway resistance [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
The bronchoprotective effect of a DI will be also examined by comparing mechanical responses to methacholine using impulse oscillometry (IOS). Single IOS will measure peripheral airway function using respiratory system reactance (X5) and peripheral resistance (R5-R20) and central resistance (R20) will be used as an index of airway narrowing.
Forced vital capacity (FVC) [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
As an index of airway closure.
FEV1/FVC [ Time Frame: After methacholine administration; will occur 2-5 minutes after 1 dose of methacholine. ]
As an index of airway narrowing (obstruction)


Estimated Enrollment:	36
Study Start Date:	October 2012
Estimated Study Completion Date:	August 2017
Estimated Primary Completion Date:	August 2017 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: Asthma Individuals diagnosed with asthma.	Other: Methacholine(MCh) Challenge Testing Visit 1: High-dose methacholine challenge test Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine. Other Names: Drug:MCh[inhalation of sequential doubling doses of MCh(0.0625-256 mg/mL)] Other names: Provocholine
Experimental: Cough Variant Asthma Individuals diagnosed with cough variant asthma.	Other: Methacholine(MCh) Challenge Testing Visit 1: High-dose methacholine challenge test Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine. Other Names: Drug:MCh[inhalation of sequential doubling doses of MCh(0.0625-256 mg/mL)] Other names: Provocholine
Experimental: Mch-induced cough w/normal airway sensitivity Individuals with chronic cough normal PC20 MCh(>16 mg/mL) & who cough during Mch challenge testing.	Other: Methacholine(MCh) Challenge Testing Visit 1: High-dose methacholine challenge test Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine. Other Names: Drug:MCh[inhalation of sequential doubling doses of MCh(0.0625-256 mg/mL)] Other names: Provocholine
Experimental: Normal Individuals with no history of asthma or chronic cough	Other: Methacholine(MCh) Challenge Testing Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step. Visit 2: Subjects will perform the opposite protocol, based on their first visit: Other Names: Drug:MCh[inhalation of sequential doubling doses of MCh(0.0625-256 mg/mL)] Other names: Provocholine

Detailed Description:

Asthma is a chronic respiratory condition characterized by eosinophilic airway inflammation. Individuals with classic asthma experience paroxysmal symptoms including cough, wheeze, shortness of breath and chest tightness. Cough variant asthma (CVA) is asthma in which chronic cough (cough lasting eight weeks or more) is the sole or predominant symptom of asthma. The pathophysiologic mechanisms which differentiate asthma, CVA, and eosinophilic bronchitis without asthma are not fully understood. We have recently identified individuals with chronic cough who cough during methacholine but have normal airway sensitivity (ie. do not have asthma or CVA) and may or may not have eosinophilic bronchitis. The purpose of this research is to examine the pathophysiologic differences between three causes of chronic cough: asthma, cough variant asthma and methacholine-induced cough with normal airway sensitivity. The responses in healthy normal subjects are crucial to understand the clinical relevance of methacholine-induced cough with normal airway sensitivity.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Individuals aged 18-65 years of age with asthma, CVA and individuals with methacholine-induced cough but normal airway sensitivity. The following definitions will be used:
1. asthma: episodic respiratory symptoms occurring in association with variable airflow obstruction (Canadian Asthma Consensus Report definition);
2. CVA: chronic cough (≥8 weeks) is the sole or predominant symptom and positive methacholine challenge (PC20 ≤ 16 mg/mL) and history of cough responding to specific asthma treatment (such as inhaled steroid or 1 week trial of bronchodilator);
3. Methacholine-induced cough but normal airway sensitivity: chronic cough (≥8 weeks) is the sole or predominant symptom and negative methacholine challenges (PC20 > 16 mg/mL).
Individuals aged 18-65 years of age with no history of asthma or chronic cough.

Exclusion Criteria:

an exacerbation necessitating a change in medication, emergency department visit or hospitalizations within the previous 4 weeks
inability to perform acceptable spirometry
medical contraindications to methacholine challenge testing
1. Severe airflow limitation (FEV1 <50% predicted or <1.0 L);
2. Heart attack or stroke in last 3 months;
3. Uncontrolled hypertension, systolic BP > 200 or diastolic BP > 100;
4. Known aortic aneurysm;
5. Moderate airflow limitation <60% predicted or 1.5) is a relative contraindication;
6. Inability to perform acceptable quality spirometry;
7. Current use of cholinesterase inhibitor medication (for myasthenia gravis); and
8. Pregnant or nursing mothers.
smoking history in excess of 10 pack years

Note: Previous treatment with inhaled or systemic corticosteroids is not an exclusion criterion; medication use will be recorded and examined in the analysis.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01659476

Locations


Canada, Ontario
Kingston General Hospital at Queen's University
Kingston, Ontario, Canada, K7L 2V7

Sponsors and Collaborators

Queen's University

Investigators


Principal Investigator:	M. Diane Lougheed, MD MSc	Queen's University

More Information


Responsible Party:	Dr. Diane Lougheed, MD, Queen's University
ClinicalTrials.gov Identifier:	NCT01659476 History of Changes
Other Study ID Numbers:	2012-01
Study First Received:	July 30, 2012
Last Updated:	March 31, 2017

Keywords provided by Dr. Diane Lougheed, Queen's University:


methacholine deep inspiration bronchoprotective effect bronchodilating effect

Additional relevant MeSH terms:


Asthma Cough Respiratory Aspiration Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Respiration Disorders Signs and Symptoms, Respiratory Signs and Symptoms	Pathologic Processes Methacholine Chloride Miotics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Parasympathomimetics Bronchoconstrictor Agents Respiratory System Agents Muscarinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 27, 2017